Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||AZD9592 + Osimertinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AZD9592||AZD 9592|AZD-9592||EGFR Antibody 53 MET Antibody 27||AZD9592 is an antibody-drug conjugate (ADC) comprising a bispecific antibody that targets EGFR and MET conjugated to a topoisomerase 1 inhibitor, which potentially leads to tumor cell apoptosis and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 5737, Cancer Res (2023) 83 (7_Supplement): 5736).|
|Osimertinib||Tagrisso||AZD9291||EGFR Inhibitor 3rd gen 26||Tagrisso (osimertinib) is a third-generation EGFR inhibitor that selectively binds mutant forms of the EGF receptor, inhibiting downstream signaling and potentially reducing cell proliferation and growth in EGFR overexpressing tumors (PMID: 29151359). Tagrisso (osimertinib) is FDA-approved for use as adjuvant therapy after resection in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion or L858R, as first-line therapy in patients with metastatic NSCLC harboring EGFR exon 19 deletion or L858R, and for treatment in patients with metastatic NSCLC harboring EGFR T790M whose disease progressed after EGFR TKI therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05647122||Phase I||AZD9592 AZD9592 + Osimertinib||First in Human Study of AZD9592 in Solid Tumors (EGRET)||Recruiting||USA | ITA | FRA | ESP | CAN | AUS||5|